Vutrisiran Global Market Report 2025

The vutrisiran market size has grown rapidly in recent years. It will grow from $0.6 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, a rise in clinical trials, growing healthcare spending, a higher patient preference for non-invasive administration methods, and an increasing prevalence of genetic disorders.

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The projected growth in the forecast period is driven by expanding healthcare availability, a rising prevalence of chronic diseases, increased investment in research and development, a growing emphasis on personalized medicine, and greater awareness of the disease. Key trends include advancements in combination therapy, the adoption of targeted therapy, progress in personalized medicine, the development of digital health technologies, and innovations in biotechnology.

The increasing investment in research and development is expected to drive the growth of the vutrisiran market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to government initiatives and funding, increasing healthcare and pharmaceutical demands, sustainability efforts, and environmental concerns. Funding for research and development enables pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term efficacy and safety, leading to wider regulatory approvals. Additionally, advancements in RNA interference (RNAi) technology enhance the drug's precision, minimizing side effects and increasing patient adoption. For example, in December 2023, Eurostat, a Luxembourg-based statistical office of the European Union, reported that the European Union's research and development expenditure reached €352 billion ($384.42 billion) in 2022, reflecting a 6.34% increase from €331 billion ($361.48 billion) in the previous year. As a result, rising investments in research and development are fueling the expansion of the vutrisiran market.

Companies operating in the vutrisiran market are focusing on developing innovative treatments, such as subcutaneous RNAi therapeutics, to offer more convenient and less frequent dosing options for managing hereditary transthyretin-mediated (hATTR) amyloidosis. These therapeutics utilize RNA interference technology and are administered through injections under the skin, ensuring sustained drug release. This approach maintains consistent drug levels over time, enhancing patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For example, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) received approval from the Food and Drug Administration (FDA) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. The drug significantly alleviates neuropathy symptoms and slows disease progression. In the HELIOS-A Phase 3 study, more than 50% of patients showed a reversal or halt in disease manifestations. AMVUTTRA has demonstrated a favorable safety profile, with no drug-related discontinuations or fatalities, and features a dosing regimen that may enhance patient compliance.

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, collaborated with Alnylam Pharmaceuticals Inc. to extend the commercialization of RNAi therapeutics. This partnership seeks to increase global availability of Alnylam’s innovative RNAi treatments, particularly for patients with rare diseases, by leveraging Medison’s integrated commercialization platform across multiple regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.

The key player in the vutrisiran market is Alnylam Pharmaceuticals Inc.

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vutrisiran report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vutrisiran is a small interfering RNA (siRNA) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis. It works by silencing the transthyretin (TTR) gene, reducing abnormal TTR protein deposits responsible for polyneuropathy and organ damage. Vutrisiran helps slow disease progression while improving neurological function, mobility, and overall quality of life, offering the benefit of a longer dosing interval.

The primary drug classes for vutrisiran include antisense oligonucleotides, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules designed to target specific mRNA sequences and regulate gene expression. Vutrisiran is administered through various routes, including oral, injectable, and subcutaneous, and is suitable for different patient demographics, including pediatric, adult, and geriatric populations. It is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The vutrisiran market research report is one of a series of new reports that provides vutrisiran market statistics, including the vutrisiran industry global market size, regional shares, competitors with the vutrisiran market share, detailed vutrisiran market segments, market trends, and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.